When to Start PSA Screening
Begin PSA screening discussions at age 50 for average-risk men, age 45 for high-risk men (African Americans or first-degree relative with prostate cancer <65 years), and age 40 for very high-risk men (multiple first-degree relatives with prostate cancer <65 years), but only after shared decision-making and in men with at least 10-15 years life expectancy. 1
Risk-Stratified Approach to Screening Initiation
The evidence strongly supports a risk-stratified approach rather than universal screening at a single age:
Average-Risk Men
- Start discussions at age 50 for men with life expectancy ≥10 years 1, 2
- The US Preventive Services Task Force (2018) recommends ages 55-69, but this represents a more conservative approach 1, 3
- Recent research from the Göteborg trial demonstrates that starting screening at ages 50-54 reduces prostate cancer mortality with a number needed to invite of 176 and number needed to diagnose of 16 to prevent one death—comparable to outcomes in older age groups 4
High-Risk Men
- Start at age 45 for:
- The European Association of Urology (2018) and American Cancer Society (2016) both support this earlier initiation 1
Very High-Risk Men
- Start at age 40 for men with multiple first-degree relatives diagnosed before age 65 1, 2
- If PSA <1.0 ng/mL at age 40, defer additional testing until age 45 2
Critical Evidence Supporting Earlier Screening
The most compelling recent evidence comes from the Göteborg trial's 24-year follow-up, which demonstrates that younger age at screening initiation is associated with greater mortality reduction 5. Starting at age 55 approximately halved the risk of prostate cancer death compared to starting at age 60 5. This suggests that guidelines recommending screening start at ages 55-69 may underestimate the benefit of programs starting at 50-55 years 5, 4.
Mandatory Shared Decision-Making
Never screen without informed discussion of benefits and harms 1, 2. This is not optional—all major guidelines from 2018 emphasize this requirement:
Benefits to Discuss:
- Screening reduces prostate cancer mortality by approximately 21% (ERSPC data) 3
- Prevents approximately 1.3 deaths per 1000 men screened over 13 years 3
- Prevents approximately 3 cases of metastatic disease per 1000 men 3
Harms to Discuss:
- Overdiagnosis: 37 additional diagnoses needed per 1 prostate cancer death prevented 6
- Biopsy complications: pain, infection, bleeding 1
- Treatment complications: 20% develop long-term urinary incontinence, 67% experience erectile dysfunction after radical prostatectomy 3
- Psychological burden from false-positives and cancer diagnosis 2
When NOT to Screen
Do not offer screening to: 1, 2
- Men aged ≥70 years (strong recommendation against) 1
- Men with life expectancy <10-15 years regardless of age 1
- Men who do not express preference for screening after informed discussion 3
- Men aged <40 years (even high-risk populations) 1
Common Pitfalls to Avoid
Screening elderly men with comorbidities: Up to 33% of elderly US men with competing medical conditions undergo inappropriate screening 1
Screening without discussion: Two-thirds of US men report no discussion about advantages, disadvantages, or uncertainties 1
Underscreening high-risk populations: African Americans are paradoxically less likely to be screened despite higher risk 1
Using outdated thresholds: While PSA >4.0 ng/mL historically triggered biopsy, risk-adapted approaches using lower thresholds (2.5-3.0 ng/mL) with reflex testing are now preferred 2, 7
Screening Intervals After Initiation
Once screening begins:
- PSA <2.5 ng/mL: Screen every 2 years 2
- PSA ≥2.5 ng/mL: Screen annually 2
- PSA <1.0 ng/mL at age 60: Lifetime risk of prostate cancer death <0.3%; less intensive screening appropriate 7
The evidence clearly demonstrates that 90% of prostate cancer deaths occur in men in the top 10% for PSA, supporting risk-stratified intervals 7.